OUR TEAM
TEAM
Anand Padmanabhan MD, PhD
Chief Scientific Officer
Chief Medical Officer
Dr. Anand Padmanabhan, MD PhD is a Laboratory Medicine and Transfusion Medicine/Apheresis-trained physician. He received his medical degree from Thanjavur Medical College (India), PhD in Biochemistry from Brown University, and trained in leading programs in Laboratory Medicine (College of Physicians and Surgeons of Columbia University) and Transfusion Medicine/Apheresis (University of Pittsburgh Medical Center). He served on the faculty of the Blood Research Institute of the BloodCenter of Wisconsin for 9+ years and is currently a physician-scientist at the Mayo Clinic in Phoenix, AZ. He is funded by the NIH to study Heparin induced Thrombocytopenia and thrombosis (HIT), a major cause of morbidity (30% thrombosis rate) and mortality (10%) in heparin-treated patients. Dr. Padmanabhan's interests include HIT epidemiology, pathogenesis, diagnosis and treatment and he has published in these areas in leading journals such as Blood, Chest and Lancet Haematology.
Steven Visuri
PhD
President
CEO
As CEO of Stem Pharm, he has raised $8M to advance novel therapeutics for Alzheimer’s disease and epilepsy using a neural organoid discovery platform. Previously, Steve co-founded FloraSeq, which developed one of the first capsule-based microbiome treatments for gastrointestinal diseases. Earlier in his career, he served as CSO and VP of Business Development at Prodesse, leading the FDA clearance of multiple infectious disease diagnostic assays and managing its $72M acquisition by Gen-Probe, later acquired by Hologic.
Steve began his career at Lawrence Livermore National Laboratory, developing innovative medical technologies and securing patents that were successfully out-licensed and became the foundation for multiple startups. An active supporter of Wisconsin’s startup community, he is a member of Golden Angels Investors. He earned his B.S. from Marquette University and his Ph.D. in Biomedical Engineering from Northwestern University.
Curtis Jones
BS
VP, Research & Innovation
Curtis received his Bachelor's of Science in Chemistry from the University of Wisconsin-Milwaukee. He has participated in and led key studies on HIT pathophysiology, diagnosis and treatment and authored numerous papers in high impact journals on HIT diagnosis, treatment and pathogenesis. He is intimately familiar with the technical and scientific aspects of HITDx development, and leads this patient-impacting effort.